Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 18Recruiting 5Withdrawn 2Unknown 2Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms, Plasma Cell 14Recurrence 12Leukemia 12Vomiting 11Lymphoma, Extranodal NK-T-Cell 11Lymphoma 11Neoplasms 9Nausea 6Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Paraproteinemias 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Lymphohistiocytosis, Hemophagocytic 3Lung Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Blood Protein Disorders 3Renal Insufficiency 2Postoperative Nausea and Vomiting 2Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2

Interventions

Cyclophosphamide 12Etoposide 10Doxorubicin 9Brentuximab Vedotin 8fludarabine phosphate 7Vinblastine 7Dacarbazine 7Bleomycin 7Vincristine 6Melphalan 6camrelizumab 5Radiotherapy 5Nivolumab 5Mycophenolic Acid 5Decitabine 5pembrolizumab 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Gemcitabine 4Filgrastim 4Cytarabine 4Cyclosporine 4Busulfan 4Bendamustine Hydrochloride 4ABVD protocol 4Tacrolimus 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Ifosfamide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Hodgkin Disease × Dexamethasone × Clear all
NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1 Unknown
72 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT00025636 2013-09-17

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 3 Unknown
220 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡